Tarsus Pharmaceuticals, Inc. (TARS)
| Market Cap | 3.21B |
| Revenue (ttm) | 451.36M |
| Net Income (ttm) | -66.42M |
| Shares Out | 42.56M |
| EPS (ttm) | -1.59 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 445,976 |
| Open | 75.75 |
| Previous Close | 75.87 |
| Day's Range | 74.06 - 76.92 |
| 52-Week Range | 38.51 - 85.25 |
| Beta | 0.58 |
| Analysts | Strong Buy |
| Price Target | 80.56 (+6.67%) |
| Earnings Date | Feb 23, 2026 |
About TARS
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner ... [Read more]
Financial Performance
In 2025, Tarsus Pharmaceuticals's revenue was $451.36 million, an increase of 146.71% compared to the previous year's $182.95 million. Losses were -$66.42 million, -42.52% less than in 2024.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for TARS stock is "Strong Buy." The 12-month stock price target is $80.56, which is an increase of 6.67% from the latest price.
News
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
Tarsus Pharmaceuticals: Q4 Results Highlight Xdemvy Blockbuster Potential
Tarsus Pharmaceuticals remains a Strong Buy, driven by Xdemvy's robust growth and management's $2B+ peak sales target. FY 2025 revenue surged 150% to $451M, with 2026 guidance at $670–$700M and 93% gr...
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call Transcript
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors
IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutic...
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026
IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Monday, February 23, 2...
Allspring Emerging Growth Fund Q4 2025 Performance Review
After years of underinvestment and production delays across the aerospace industry, ATI is now capitalizing on a surge in demand fueled by Boeing and Airbus' historically large backlogs for new aircra...
Tarsus Pharmaceuticals: Xdemvy Momentum Continues In Q3
Tarsus Pharmaceuticals, Inc. is upgraded to Strong Buy with a 12-month price target of $100/share, driven by Xdemvy's rapid commercialization. Xdemvy remains the only approved treatment for Demodex bl...
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2025 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. ( TARS) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants David Nakasone - Head of Investor Relations Bobak Azamian - Co-Founder, President, CEO & C...
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements
Delivered quarterly XDEMVY ® net sales of approximately $119 million, up approximately 147% year-over-year
Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 4, 2...
Tarsus Pharmaceuticals: Considering If The Big Marketing Push Will Pay Off
TARS has passed the milestone of $100M in sales per quarter with Xdemvy. TARS guides for softer Q3'25 growth due to seasonality, but expects direct-to-consumer campaigns and reimbursement to drive str...
Top 2 Health Care Stocks That May Fall Off A Cliff In August
As of Aug. 20, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2025 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Aziz Mottiwala - Chief Commercial Officer Bobak R. Azamian - Co-Founder, Pre...
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements
Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY ® launch, an increase of 152% year over year
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, August 6, 2...
Tarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay Off
TARS has been marketing Xdemvy (lotilaner) aggressively, with Q1'25 seeing advertisement on network TV, moving beyond previous advertising on streaming platforms. TARS can expand lotilaner beyond Demo...
Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown
GREENFIELD, Ind. , May 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEM...
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants David Nakasone – Head-Investor Relations Bobby Azamian – Chief Executive Office...
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements
Generated $78.3 million in net product sales of XDEMVY ® , an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025...
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting
IRVINE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will present four distinct data sets highlighting the global prevalence and real-world patient burden of ...
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized underwritten public offering of 2,8...
Tarsus Announces Proposed $100.0 Million Public Offering
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the commencement of an underwritten public offering of $100.0...
Tarsus Pharma: Strong Execution In Xdemvy Commercialization
Tarsus Pharmaceuticals' Xdemvy, the first approved treatment for Demodex blepharitis, generated $180M in 2024 sales, with significant growth potential in a large addressable market. Analysts project T...
Tarsus to Participate in Upcoming Investor Conference
IRVINE, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the Barclays 27th Annual Global H...